Adagene Inc.
Adagene Inc. (ADAG): 5 pipeline candidates · ~14 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.4 months
D/E 0.75 · 0% dilution
Lead: Phase 1
5 candidates
N/A
N/A
A transparent, data-derived signal for Adagene Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$233.2M
Cash
$74.5M
Quarterly Burn
$15.7M
Runway
14.4 mo
Revenue
$7.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| ADG126 | Phase 1 |
| NKT2152 | Phase 1 |
| Tiragolumab | Phase 1 |
| Tocilizumab | Phase 1 |
| TPST-1120 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$3.4M
| Holder | Shares | Value |
|---|---|---|
| ameriprise financial inc | 607,903 | $2.4M |
| morgan stanley | 66,148 | $259K |
| smartharvest portfolios, llc | 40,312 | $158K |
| renaissance technologies llc | 34,533 | $135K |
| jane street group, llc | 30,425 | $119K |
| alyeska investment group, l.p. | 20,710 | $81K |
| royal bank of canada | 16,850 | $66K |
| nomura holdings inc | 14,710 | $58K |
| quadrature capital ltd | 11,617 | $46K |
| geode capital management, llc | 10,309 | $40K |
Showing top 10 of 18 institutional holders of Adagene Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Adagene Inc.'s pipeline?
Adagene Inc. (ADAG) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Adagene Inc.'s lead drug candidate?
Adagene Inc.'s most advanced tracked candidate is ADG126 (Phase 1) for Advanced Liver Cancers (Morpheus.
What is Adagene Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Adagene Inc. has approximately 14.4 months of cash runway.
What is Adagene Inc.'s market capitalization?
Adagene Inc.'s market capitalization is approximately $233.2M.
Who is the CEO of Adagene Inc.?
Dr. Peter P. Luo Ph.D. is the chief executive officer of Adagene Inc. (ADAG).
Get the full picture on Adagene Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.